MARKET

BCAB

BCAB

Bioatla, Inc.
OTCID
1.490
-0.245
-14.12%
Closed 15:59 08/31 EDT
OPEN
1.760
PREV CLOSE
1.735
HIGH
2.100
LOW
1.310
VOLUME
58.51K
TURNOVER
103.80K
52 WEEK HIGH
71.50
52 WEEK LOW
1.310
MARKET CAP
2.48M
P/E (TTM)
-0.0583
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
BioAtla Faces Nasdaq Delisting, Plans OTC Market Move
TipRanks · 3d ago
BioAtla To Be Delisted From Nasdaq Following Listing Council Decision; Trading Suspension Effective August 31, With Shares Expected To Transition To OTC Markets
Benzinga · 3d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at BCAB last week (0817-0821)?
Weekly Report · 08/24 09:18
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/21 21:06
Weekly Report: what happened at BCAB last week (0810-0814)?
Weekly Report · 08/17 09:18
More
About BCAB
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Webull offers Bioatla Inc stock information, including OTCID: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.